Loading organizations...
§ Private Profile · Suwanee, GA, USA
Medical technology for women's reproductive health. Develops minimally invasive devices for permanent birth control and infertility treatment.
Based in Suwanee, Georgia, Femasys develops minimally invasive, in-office medical technologies focused on women's reproductive health, specifically permanent birth control and infertility treatments. The company addresses a domestic market of over 9 million women contending with infertility through its proprietary nonsurgical and nonhormonal devices, alongside cervical cancer screening tools. After operating with traditional venture capital backing, the enterprise transitioned to public markets via a 2021 initial public offering on the Nasdaq that netted $31.6 million. Its intellectual property portfolio encompasses more than 100 United States and international patents covering lead products like FemBloc and FemaSeed. Corporate governance and strategic direction are overseen by a board of directors that includes industry figures such as Charlie Larsen, Joshua Silverman, Keith Kendall, and Alistair Milnes. Femasys was originally founded in 2004 by biochemist and principal inventor Kathy Lee-Sepsick.
Femasys has raised $54.2M across 3 funding rounds.
Femasys has raised $54.2M in total across 3 funding rounds.
Femasys has raised $54.2M in total across 3 funding rounds.
Femasys's investors include Legacy Capital Partners, Ernest Mario, Salem Partners.
Femasys has raised $54.2M across 3 funding rounds. Most recently, it raised $40.0M Series C in December 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2016 | $40M Series C | — | — | Announced |
| Apr 30, 2015 | $10.2M Venture Round | Legacy Capital Partners, Ernest Mario, Salem Partners | — | Announced |
| Jun 8, 2012 | $4M Debt Financing | — | — | Announced |